Last updated: September 4, 2026
The fixed-dose combination of bupropion hydrochloride and dextromethorphan hydrobromide is marketed in the United States as Auvelity by Axsome Therapeutics. FDA approved Auvelity in August 2022 for major depressive disorder in adults. The product combines 105 mg of bupropion hydrochloride with 45 mg of dextromethorphan hydrobromide in an extended-release tablet taken twice daily.[1]
Auvelity has converted two low-cost generic ingredients into a differentiated branded antidepressant. Its commercial trajectory depends on prescription growth, payer coverage, physician adoption, and the ability to maintain market exclusivity against future generic combination products. Axsome reported rapid sales expansion after launch, but the product remains exposed to concentration risk because it is the company’s principal commercial asset.
What is the approved drug combination of bupropion and dextromethorphan?
Auvelity is an oral, extended-release combination product with a dual pharmacological rationale.
| Product characteristic |
Auvelity |
| Active ingredients |
Bupropion hydrochloride and dextromethorphan hydrobromide |
| Strength |
105 mg bupropion HCl/45 mg dextromethorphan HBr per tablet |
| Initial dose |
One tablet daily for three days |
| Maintenance dose |
One tablet twice daily |
| FDA indication |
Major depressive disorder in adults |
| Approval date |
August 18, 2022 |
| Sponsor |
Axsome Therapeutics |
| Dosage form |
Extended-release oral tablet |
| Controlled-substance status |
Not scheduled under the federal Controlled Substances Act |
| FDA pathway |
Section 505(b)(2) new drug application |
Bupropion is a norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist. Dextromethorphan has activity at the N-methyl-D-aspartate receptor, sigma-1 receptor and other central nervous system targets. Bupropion also inhibits CYP2D6, which increases and prolongs dextromethorphan exposure.[1]
The product’s commercial claim is based on a potentially faster and more differentiated antidepressant effect than conventional monoaminergic therapies. The pivotal ASCEND study showed statistically significant improvement in depressive symptoms compared with bupropion alone, although commercial adoption remains dependent on real-world prescribing and reimbursement.[2]
How large is the market for Auvelity and its active ingredients?
The addressable market is large, but the branded opportunity is narrower than the overall depression market.
The United States has tens of millions of adults diagnosed with depression, while generic selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and bupropion account for most treated patients. Auvelity competes for patients who have inadequate response, intolerance, delayed response or inadequate remission on standard antidepressants.
The market has four principal segments:
- First-line treatment, dominated by low-cost generic antidepressants.
- Treatment-resistant depression, where physicians may consider Auvelity, atypical antipsychotic augmentation, ketamine-based products or electroconvulsive therapy.
- Patients seeking a noncontrolled oral alternative to intranasal esketamine.
- Commercially insured patients for whom prior authorization and copay support determine access.
Auvelity’s main commercial advantage is an oral, noncontrolled product with a differentiated mechanism. Its main disadvantage is price relative to generic bupropion and generic dextromethorphan products, which cannot be substituted automatically because no approved generic equivalent existed at the time of launch.
What were Auvelity’s sales and financial trajectory?
Axsome’s reported revenue increased sharply after Auvelity entered the market. The product was launched in late 2022, making 2023 the first full commercial year.
| Period |
Commercial status |
Reported financial direction |
| 2022 |
FDA approval and initial launch |
Limited launch-period revenue |
| 2023 |
First full year of commercialization |
Auvelity became Axsome’s primary revenue source |
| 2024 |
Expansion of prescribing, payer coverage and field commercial activity |
Substantial year-over-year product-revenue growth |
| 2025 onward |
Growth phase with increasing exposure to payer controls and competitive entry risk |
Dependent on refill persistence, new-patient starts and exclusivity |
Axsome reported approximately $132 million in 2023 net product revenue, primarily from Auvelity.[3] Public company reporting indicates that 2024 revenue increased materially as prescription volume expanded and the commercial infrastructure matured.[4]
The financial model is attractive because the active ingredients are inexpensive relative to the branded net selling price. The major costs are commercial promotion, patient-support programs, manufacturing, distribution, rebates, co-pay assistance and market-access contracting. Gross margin should remain favorable if the product maintains branded pricing, although gross-to-net deductions will increase as the product moves deeper into managed-care formularies.
What drives Auvelity revenue growth?
Revenue growth depends on five operating variables:
- New prescription volume from psychiatrists and primary-care physicians.
- Refill persistence after the first one to three months.
- Expansion of commercial and government payer coverage.
- Reduction in prior-authorization friction.
- Conversion of patients from generic antidepressants and other branded therapies.
The product’s early growth benefited from a large untreated or inadequately treated patient population and the absence of a direct generic equivalent. Sales expansion is likely to become less linear as Axsome reaches higher-prescribing psychiatric practices and faces increasingly selective payer utilization management.
How does Auvelity compare with competing depression treatments?
| Product or class |
Sponsor or manufacturers |
Administration |
Key commercial distinction |
Principal competitive weakness |
| Auvelity |
Axsome Therapeutics |
Oral, twice daily |
Noncontrolled oral combination with differentiated mechanism |
Branded price and limited long-term market history |
| Generic bupropion |
Multiple generic manufacturers |
Oral |
Low cost and broad physician familiarity |
No dextromethorphan component |
| SSRIs and SNRIs |
Multiple manufacturers |
Oral |
First-line guideline use and low cost |
Delayed response, sexual dysfunction and other tolerability concerns |
| Spravato |
Johnson & Johnson |
Intranasal, supervised administration |
Established treatment-resistant depression franchise |
Controlled substance, clinic administration and monitoring |
| Trintellix |
Takeda/Lundbeck |
Oral |
Branded multimodal antidepressant |
Mature branded competition and payer restrictions |
| Zurzuvae |
Biogen/Sage Therapeutics |
Oral, short-course treatment |
Postpartum depression indication |
Narrower indication and short treatment window |
| Atypical antipsychotic augmentation |
Multiple manufacturers |
Oral |
Established treatment-resistant depression strategy |
Metabolic and neurologic adverse-effect concerns |
Auvelity is most directly comparable with branded treatments for inadequate response to first-line antidepressants. Spravato has a stronger treatment-resistant-depression identity but carries higher administration complexity. Generic bupropion is the most important price comparator because it is one component of Auvelity and is widely prescribed.
What patents protect bupropion hydrochloride and dextromethorphan hydrobromide?
The basic pharmaceutical ingredients are not protected by meaningful new-molecule exclusivity. Bupropion hydrochloride is an old generic active ingredient, and dextromethorphan hydrobromide has long been used in over-the-counter cough products.
Auvelity’s protection is based primarily on combination therapy, dosing, pharmacokinetic interaction and treatment-method claims.
| Protection category |
Relevance to Auvelity |
| Bupropion composition patents |
Largely expired or commercially irrelevant |
| Dextromethorphan composition patents |
Largely expired or commercially irrelevant |
| Fixed-dose combination patents |
Potentially important |
| Method-of-use patents |
Important for depression treatment and dosing claims |
| Extended-release formulation patents |
Important if they cover the marketed tablet |
| Pharmacokinetic or CYP2D6-based claims |
Potentially useful against nonidentical combination products |
| Manufacturing patents |
Relevant if they cover the commercial release profile or difficult solid dosage process |
Axsome’s issued patent estate has included patents directed to the use of dextromethorphan and bupropion for depressive disorders and related dosing regimens. Public company filings identify issued U.S. patents for the AXS-05 program, including U.S. Patent No. 10,576,081, with additional continuation or related patents disclosed in later filings.[3,5]
The practical protection period extends well beyond the five-year new chemical entity period because the product relies on patents covering the combination and its clinical use. Exact Orange Book patent status and expiration dates can change as continuation patents issue or listings are withdrawn. The commercial risk is therefore determined by the surviving claims, not by the age of either ingredient.
What is the Orange Book status of Auvelity?
Auvelity is an FDA-approved prescription drug listed in Drugs@FDA and the Orange Book. Its regulatory exclusivity is based on the new drug application and associated patent listings, rather than on exclusivity for either active ingredient alone.[1,6]
The product was approved through the 505(b)(2) pathway. That pathway permits reliance on existing information about one or more active ingredients while requiring the sponsor to establish the safety and effectiveness of the proposed combination and indication.
The principal regulatory protections are:
- Five years of new chemical entity exclusivity does not apply in the same manner as it would to an entirely new active moiety because the product contains previously known active ingredients.
- Three-year approval-related exclusivity may protect new clinical investigations essential to approval.
- Listed patents can support a Hatch-Waxman stay if a generic applicant files a valid Paragraph IV certification and Axsome sues within the statutory period.
- Pediatric exclusivity could extend applicable regulatory protection if FDA grants it based on completed pediatric studies.
The combination’s regulatory position is stronger than the ingredient position because a generic applicant must address the specific approved product, formulation and listed patents.
When does Auvelity lose exclusivity?
Auvelity does not have a single practical loss-of-exclusivity date. Generic entry depends on the earliest successful challenge to relevant patents, the expiration of all blocking patents, regulatory exclusivity and any litigation settlement.
A simplified timeline is:
| Event |
Timing |
| FDA approval |
August 2022 |
| Commercial launch |
Late 2022 |
| First full commercial year |
2023 |
| Likely early patent challenges |
After generic applicants can file ANDAs with Paragraph IV certifications |
| Base-case protected commercial period |
Mid-to-late 2030s, subject to patent validity and claim scope |
| Potential later protection |
Continuation patents and formulation or method patents could extend selected claims into the late 2030s or beyond |
Axsome has publicly described patent protection for the AXS-05 program extending into the 2030s.[3,5] A precise generic entry date cannot be inferred from the original approval date. The decisive questions are whether a generic applicant can design around the claims, whether the patents survive litigation and whether Axsome settles.
Which companies are challenging Auvelity with Paragraph IV filings?
No material public Paragraph IV challenge to Auvelity had been disclosed in Axsome’s public reporting through the company’s 2024 filings. That does not eliminate future challenge risk.
The likely challengers are large generic manufacturers with CNS commercialization capabilities, including Teva, Sandoz, Viatris, Hikma and Amneal. A generic applicant could pursue:
- A fixed-dose combination equivalent.
- A formulation with different release characteristics.
- Separate bupropion and dextromethorphan products marketed for an equivalent therapeutic purpose.
- A method-of-use strategy that avoids asserted treatment claims.
A direct generic substitution would face formulation, bioequivalence and patent-certification issues. The commercial opportunity may be attractive because manufacturing two established ingredients is less difficult than developing a new chemical entity, but the combination’s controlled-release profile and pharmacokinetic interaction create technical barriers.
What generic launch scenarios exist for Auvelity?
At-risk launch before final patent resolution
A generic manufacturer could launch after a favorable court decision, settlement provision or legal determination that the relevant patents do not block marketing. An at-risk launch could expose the manufacturer to damages and an injunction if Axsome later prevails.
Launch after patent expiration
This is the lowest-risk scenario for the generic applicant. It would likely produce rapid price erosion, although branded retention could remain meaningful if Axsome maintains physician loyalty, patient-support services and differentiated clinical positioning.
Settlement with a licensed entry date
A settlement could permit generic entry before the latest patent expiration. The economic value of such an agreement would depend on the entry date, volume limits, authorized-generic provisions and restrictions on formulation or indication.
No public settlement agreement involving Auvelity had been reported through 2024.
How strong is the Auvelity patent estate?
The estate is commercially meaningful but less robust than a new-molecule composition-of-matter estate.
Strengths
- The combination addresses a specific clinical use rather than a generic ingredient.
- Bupropion’s CYP2D6 inhibition supports a pharmacokinetic rationale for combining the ingredients.
- The product has an FDA-approved indication and commercial use, which can strengthen the practical value of method patents.
- Extended-release formulation claims may create manufacturing and bioequivalence obstacles.
Weaknesses
- Both active ingredients are old and widely available.
- Patentability may depend on claim specificity, unexpected clinical results and formulation details.
- Generic manufacturers can attempt noninfringing formulations or alternative dosing regimens.
- Method-of-use claims can be harder to enforce than composition claims because direct infringement often depends on labeling and actual use.
- Patent validity challenges could target obviousness, written description and enablement.
The estate is strongest if it includes claims that tightly connect the specific formulation, release profile, dose and therapeutic indication. It is weaker if generic applicants can reproduce the clinical effect with separate or materially different products without practicing the asserted claims.
Is there biosimilar risk for this product?
There is no biosimilar risk. Auvelity is a small-molecule oral drug, not a biologic. Future competition would come through abbreviated new drug applications, 505(b)(2) applications or other small-molecule regulatory pathways.
This distinction matters commercially. Biosimilar entry usually involves reference-product interchangeability and complex manufacturing comparability. Auvelity’s main threat is conventional generic substitution or therapeutic substitution by other oral or intranasal antidepressants.
What licensing deals affect Auvelity?
Axsome has positioned Auvelity as an internally controlled commercial product and has not disclosed a major out-licensing transaction that transfers the U.S. commercial economics to another pharmaceutical company. The company has retained control of development, regulatory filings and commercial promotion.
The absence of a large licensing partner preserves upside but leaves Axsome responsible for:
- Sales-force investment.
- Managed-care negotiations.
- Manufacturing scale-up.
- Pharmacovigilance.
- Legal defense of the patent estate.
- Revenue concentration and commercial execution risk.
What manufacturing and intellectual-property barriers protect the product?
Manufacturing barriers are moderate rather than fundamental. The active ingredients are established and available from generic suppliers. The principal technical issues involve:
- Consistent extended-release performance.
- Control of bupropion and dextromethorphan dissolution profiles.
- Dose uniformity.
- Stability and impurity control.
- Bioequivalence against the marketed tablet.
- Reproducibility of the pharmacokinetic interaction.
A generic manufacturer with a capable oral-solid-dose platform could likely develop a competing product. The barrier is therefore more legal and regulatory than raw-material access.
What is the investment outlook for Auvelity revenue?
The base commercial thesis is continued growth from a low launch base, followed by a slower expansion curve as the product reaches broader payer and prescriber penetration.
Upside drivers
- Greater recognition of rapid or differentiated antidepressant response.
- Expanded use in treatment-resistant or inadequate-response patients.
- Improved commercial formulary coverage.
- Higher refill persistence.
- Additional indications supported by clinical development.
- International approvals or licensing transactions.
Downside drivers
- Prior authorization and step-therapy requirements.
- High patient co-pay exposure.
- Generic substitution after patent challenges.
- Competition from Spravato, Zurzuvae and future rapid-acting antidepressants.
- Adverse-event concerns, including seizure risk, hypertension, insomnia and drug interactions.
- Dependence on a single commercial product.
For Axsome, Auvelity revenue has a high contribution to corporate valuation because the company’s development-stage pipeline does not yet provide the same scale of recurring commercial sales. That creates operating leverage if sales rise, but it also increases downside sensitivity to prescription trends, payer decisions and patent litigation.
Key Takeaways
- Auvelity is the branded fixed-dose combination of bupropion hydrochloride and dextromethorphan hydrobromide.
- FDA approved it in August 2022 for major depressive disorder in adults.
- The active ingredients are old generic compounds; the commercial protection comes from combination, formulation, dosing and method-of-use patents.
- Axsome reported approximately $132 million of Auvelity-related net product revenue in 2023, with substantial growth reported in 2024.
- The product competes with generic antidepressants, Spravato, Trintellix, Zurzuvae and augmentation therapies.
- No material public Paragraph IV challenge or settlement had been disclosed through 2024.
- Auvelity has no biosimilar risk because it is a small-molecule oral product.
- The likely loss-of-exclusivity window is in the 2030s, subject to patent validity, continuation patents, litigation and settlements.
- The principal financial risk is revenue concentration in one branded product.
- The principal legal risk is that generic manufacturers design around method-of-use or formulation claims covering the marketed product.
FAQs About Bupropion-Dextromethorphan Market Exclusivity
Is Auvelity more valuable than generic bupropion?
Yes, commercially. Auvelity combines bupropion with dextromethorphan and has FDA approval for major depressive disorder, allowing Axsome to charge a branded price. Generic bupropion remains a major low-cost substitute and limits pricing power.
Can a generic company sell bupropion and dextromethorphan separately?
A company can market the individual ingredients if it has the required FDA approvals, but separate products would not automatically be substitutable for Auvelity. The generic company would need to address the combination’s clinical labeling, formulation and patent claims.
Is dextromethorphan in Auvelity the same ingredient used in cough medicine?
The active moiety is the same, but Auvelity uses dextromethorphan hydrobromide in a prescription extended-release combination with bupropion. The formulation, dose and therapeutic indication differ from typical over-the-counter cough products.
Could Auvelity receive additional FDA indications?
Yes. Additional indications could extend commercial reach, but each indication would require supporting clinical evidence and could create new patent or regulatory exclusivity opportunities only if the statutory requirements are met.
What would happen to Auvelity sales after generic entry?
A direct generic equivalent would likely cause a rapid decline in net price and branded market share. The extent of revenue erosion would depend on the number of entrants, the settlement date, payer substitution rules, authorized-generic strategy and whether Axsome retains a clinically differentiated position.
References
-
U.S. Food and Drug Administration. (2022). Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) prescribing information. FDA.
-
Trivedi, M. H., et al. (2022). A randomized controlled trial of dextromethorphan-bupropion in major depressive disorder. American Journal of Psychiatry, 179(7), 490-502.
-
Axsome Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Axsome Therapeutics, Inc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,576,081: Methods of treating depression using dextromethorphan and bupropion. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book and Drugs@FDA records for Auvelity. FDA.
